Compounds > 1,2,3,4-tetrahydropyrimidine-2-thione
Page last updated: 2024-12-10
1,2,3,4-tetrahydropyrimidine-2-thione
Description
## 1,2,3,4-Tetrahydropyrimidine-2-thione (THPT)
**1,2,3,4-Tetrahydropyrimidine-2-thione** (THPT) is a heterocyclic compound with a sulfur atom in the 2-position of a pyrimidine ring.
**Why it's important for research:**
* **Antioxidant properties:** THPT has been shown to exhibit significant antioxidant activity, which is important for preventing oxidative stress and damage to cells. Oxidative stress is implicated in various diseases like cancer, cardiovascular diseases, and neurodegenerative disorders.
* **Anti-inflammatory properties:** THPT has also been found to possess anti-inflammatory properties, potentially due to its ability to inhibit the production of pro-inflammatory mediators like TNF-α and IL-6. This makes it a potential therapeutic target for inflammatory conditions like arthritis, asthma, and inflammatory bowel disease.
* **Anti-cancer activity:** Several studies have shown that THPT exhibits anticancer activity against various cancer cell lines, including breast, lung, and colon cancer. It has been found to induce apoptosis (programmed cell death) and inhibit tumor growth.
* **Neuroprotective effects:** THPT has demonstrated neuroprotective effects, particularly in models of Alzheimer's disease and stroke. It can protect neurons from damage induced by oxidative stress and inflammation.
* **Other potential applications:** THPT has been investigated for its potential applications in other areas, such as:
* **Anti-diabetic activity:** THPT has shown promise in controlling blood sugar levels in diabetic models.
* **Antiviral activity:** Some studies suggest that THPT may possess antiviral activity against certain viruses.
* **Antimicrobial activity:** THPT has demonstrated antimicrobial activity against bacteria and fungi.
**Research focus:**
Current research focuses on:
* Understanding the mechanisms underlying the various pharmacological activities of THPT.
* Developing THPT derivatives with improved potency and pharmacokinetic properties.
* Evaluating the safety and efficacy of THPT in preclinical and clinical trials for various diseases.
**Overall, 1,2,3,4-Tetrahydropyrimidine-2-thione (THPT) is a promising lead compound with a wide range of potential therapeutic applications. Its antioxidant, anti-inflammatory, anti-cancer, and neuroprotective properties make it a valuable target for research in the fields of medicine, pharmacy, and biotechnology.**
1,2,3,4-tetrahydropyrimidine-2-thione: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 5260030 |
SCHEMBL ID | 489207 |
MeSH ID | M0500992 |
Synonyms (9)
Synonym |
AKOS006355522 |
86425-08-3 |
SCHEMBL489207 |
DTXSID20413931 |
3,4-dihydro-2(1h)-pyrimidinethione |
3,4-dihydropyrimidine-2(1h)-thione |
1h 4h-2-pyrimidinethiol |
4h-2-pyrimidinethiol |
1,2,3,4-tetrahydropyrimidine-2-thione |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.50 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.30 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |